Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.

Summary

This was an open-label, multi-center, randomized phase 2 study. This is a two-stage design.In the first stage, two dose groups were set up, the 100 mg bid dose group and the 200 mg qd dose group, which were randomized at 1:1, with 50 subjects in each group, and a total of 100 cases in the two groups. In the second stage, approximately 36 subjects were added to the randomized group.

Timeline

Start

2019-01-08

Primary completion

2021-02-02

Completion

2021-02-02

Drugs

Indications